| Q38588894 | 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. |
| Q28215071 | A RING finger protein Praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Necdin family protein, Dlxin-1 |
| Q34074758 | A Screening Assay to Identify Agents That Enhance T-Cell Recognition of Human Melanomas |
| Q27311561 | A biased competition theory of cytotoxic T lymphocyte interaction with tumor nodules |
| Q40144423 | A cis-eQTL genetic variant of the cancer-testis gene CCDC116 is associated with risk of multiple cancers. |
| Q39066797 | A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet |
| Q24307739 | A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma |
| Q28288235 | A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma |
| Q30931923 | A note from history: Landmarks in history of cancer, part 7. |
| Q41421781 | A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. |
| Q38287365 | A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. |
| Q36365847 | A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene |
| Q34416464 | A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer |
| Q36365601 | A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells |
| Q71803282 | A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours |
| Q39874070 | A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro |
| Q40963061 | A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells. |
| Q24564781 | A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening |
| Q35664087 | Ablation of Cbl-b provides protection against transplanted and spontaneous tumors |
| Q53983292 | Activated Human CD4+ T Cells Induced by Dendritic Cell Stimulation Are Most Sensitive to Transforming Growth Factor-β: Implications for Dendritic Cell Immunization against Cancer |
| Q77364836 | Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma |
| Q35990356 | Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen |
| Q38116170 | Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme |
| Q35886393 | Adding fuel to the fire: immunogenic intensification |
| Q40632527 | Adenoviral Transgene Ubiquitination Enhances Mouse Immunization and Class I Presentation by Human Dendritic Cells |
| Q53961221 | Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma |
| Q45879294 | Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism |
| Q35177576 | Adjuvants for vaccines, a quest |
| Q38753404 | Adoptive T-Cell Therapy for Cancer |
| Q35142962 | Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction |
| Q50670947 | American Association for Cancer Research: potential target antigens for cancer immunotherapy. April 1-5, 2000, San Francisco, CA, USA. |
| Q36293682 | Amplifying TLR-MyD88 Signals within Tumor-Specific T Cells Enhances Antitumor Activity to Suboptimal Levels of Weakly Immunogenic Tumor Antigens |
| Q30442847 | An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins |
| Q57556559 | An array of immunotherapeutic strategies for B-cell lymphomas |
| Q36979263 | An autologous oral DNA vaccine protects against murine melanoma |
| Q92415300 | An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma |
| Q42614126 | An innate immune response of blood cells to tumors and tissue damage in Drosophila |
| Q40711676 | An optimum anti-melanoma response in mice immunized with fibroblasts transfected with DNA from mouse melanoma cells requires the expression of both syngeneic and allogeneic MHC-determinants |
| Q50112641 | An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice |
| Q36821149 | Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model |
| Q34002880 | Anti-idiotype vaccines for human follicular lymphoma |
| Q36914397 | Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen |
| Q42818431 | Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer |
| Q34297813 | Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer |
| Q73228020 | Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes |
| Q41646158 | Antibody-targeted superantigens in cancer immunotherapy |
| Q30840053 | Antigen arrays in T cell immunology |
| Q33752783 | Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation |
| Q24675502 | Antigen processing in vivo and the elicitation of primary CTL responses |
| Q40375567 | Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors |
| Q35773889 | Antigen-presenting cell engineering. The molecular toolbox |
| Q41202687 | Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins |
| Q39752699 | Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes |
| Q64325397 | Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice |
| Q39155725 | Antitumor activity of a polysaccharide from Pleurotus eryngii on mice bearing renal cancer |
| Q28142431 | Antitumor immunity at work in a melanoma patient |
| Q34038749 | Antitumor vaccination using peptide based vaccines. |
| Q54961397 | Approaches to Improve Chemically Defined Synthetic Peptide Vaccines. |
| Q48152277 | Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. |
| Q73795133 | Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7 |
| Q39549023 | Augmentation of cellular immune response by Ipomoea obscura and Ipobscurine alkaloid attenuates tumor growth in mice |
| Q53640046 | Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide |
| Q35048054 | Augmenting antitumor immune responses with epigenetic modifying agents |
| Q36676048 | Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. |
| Q33785039 | Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes |
| Q78045251 | B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma |
| Q41116012 | B7-mediated costimulation and the immune response |
| Q41371291 | BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes |
| Q57890248 | Bioactive Natural Peptides |
| Q34452007 | Biological and clinical developments in melanoma vaccines |
| Q36380683 | Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors |
| Q38193821 | Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State |
| Q57114951 | Breast cancer vaccination comes to age: impacts of bioinformatics |
| Q35983806 | CD24 on thymic APCs regulates negative selection of myelin antigen‐specific T lymphocytes |
| Q33747241 | CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation. |
| Q52970972 | CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells |
| Q41177628 | CD4+ cytolytic effectors are inefficient in the clearance of Listeria monocytogenes |
| Q77402954 | CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help |
| Q40876094 | CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth |
| Q37375643 | CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy |
| Q56798245 | CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholanthrene |
| Q92650598 | CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine |
| Q45160346 | CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells |
| Q56906680 | CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism |
| Q37986999 | Cancer Immunoediting in Malignant Glioma |
| Q41463105 | Cancer dormancy: opportunities for new therapeutic approaches |
| Q90060380 | Cancer immune escape: MHC expression in primary tumours versus metastases |
| Q28205027 | Cancer immunoprevention: tracking down persistent tumor antigens |
| Q35083647 | Cancer immunotherapy: the past, the present and the future |
| Q34038778 | Cancer therapy with DNA-based vaccines |
| Q27024438 | Cancer vaccines |
| Q81417332 | Cancer vaccines: on the threshold of success |
| Q44011532 | Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. |
| Q36084122 | Cell-free tumor antigen peptide-based cancer vaccines |
| Q73395758 | Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia |
| Q35067995 | Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells |
| Q55473816 | Changes in the Immunologic Phenotype of Human Malignant Glioma Cells after Passaging in Vitro |
| Q24678848 | Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination |
| Q35230265 | Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis |
| Q40378112 | Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. |
| Q35091726 | Chitosan Nanoparticles Act as an Adjuvant to Promote both Th1 and Th2 Immune Responses Induced by Ovalbumin in Mice |
| Q43680262 | Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis |
| Q36615924 | Clinical Development of Listeria monocytogenes–Based Immunotherapies |
| Q30784536 | Clinical immunotherapy for brain tumors |
| Q74272560 | Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer |
| Q41481647 | Clinical promise of tumour immunology |
| Q36671472 | Clinical significance of immune cell infiltration within gallbladder cancer |
| Q36235551 | Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines |
| Q36375152 | Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp |
| Q53411447 | Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells |
| Q46030251 | Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma |
| Q39999888 | Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. |
| Q35056551 | Contribution of HIV infection to mortality among cancer patients in Uganda |
| Q30697033 | Contribution of mass spectrometry to contemporary immunology |
| Q40764447 | Control of Advanced Choroid Plexus Tumors in SV40 T Antigen Transgenic Mice Following Priming of Donor CD8+ T Lymphocytes by the Endogenous Tumor Antigen |
| Q35623006 | Control of autoimmunity by naturally arising regulatory CD4+ T cells |
| Q36470722 | Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. |
| Q41495234 | Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens |
| Q34203603 | Cowpea mosaic virus as a vaccine carrier of heterologous antigens |
| Q35108299 | Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. |
| Q37760422 | Cross-priming in health and disease. |
| Q35107009 | Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies |
| Q39022359 | Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response |
| Q90429847 | Current Perspectives on Nasopharyngeal Carcinoma |
| Q41526891 | Cytokine Gene Transduction in the Immunotherapy of Cancer |
| Q47912519 | Cytokines and Cancer |
| Q41202957 | Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens |
| Q40568933 | Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells |
| Q36619554 | Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer. |
| Q36367821 | Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. |
| Q38041524 | DNA Hypomethylation and Activation of Germline-Specific Genes in Cancer |
| Q40732047 | DNA vaccines for cancer therapy |
| Q40649809 | Degradation of the immunogenic peptide gp100(280-288) by the monocyte-like U937 cell line. |
| Q36696751 | Demethylation of MAGE promoters during gastric cancer progression |
| Q36497106 | Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice |
| Q41649620 | Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors |
| Q41597901 | Dendritic Cells for Somatic Gene Therapy |
| Q26774345 | Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy |
| Q37821074 | Dendritic cells and immunity against cancer. |
| Q36085614 | Dendritic cells as therapeutic vaccines against cancer |
| Q73998211 | Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens |
| Q33653670 | Dendritic cells. |
| Q33541967 | Dendritic cells: a link between innate and adaptive immunity |
| Q34451999 | Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses |
| Q42819732 | Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival |
| Q37960189 | Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells |
| Q87335130 | Developing effective tumor vaccines: basis, challenges and perspectives |
| Q36293328 | Development of HVJ envelope vector and its application to gene therapy |
| Q70911259 | Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice |
| Q39586397 | Differential Response of Human and Mouse Dendritic Cells to VEGF Determines Interspecies Discrepancies in Tumor-Mediated Th1/Th2 Polarity Shift |
| Q30469600 | Direct identification of tumor-associated peptide antigens. |
| Q56896732 | Display of functional alphabeta single-chain T-cell receptor molecules on the surface of bacteriophage |
| Q37400231 | Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones |
| Q55366610 | Do structural changes of T cell receptor complex occur in tumor-bearing state? |
| Q36144696 | Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses |
| Q37307252 | Downregulation of the H-2Kd gene by siRNA affects the cytotoxicity of murine LAK cells |
| Q30583272 | Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction |
| Q88092291 | EPSAH, an exopolysaccharide from Aphanothece halophytica GR02, improves both cellular and humoral immunity as a novel polysaccharide adjuvant |
| Q35210490 | Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion |
| Q52044278 | Effects of thymectomy and tolerance induction on tumor immunity in adult Xenopus laevis |
| Q34619847 | Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells. |
| Q35064126 | Emerging cancer-targeted therapies |
| Q77319990 | Enhancement of Antigen-Specific IFN-γ Production from CD8+T Cells by a Single Amino Acid-Substituted Peptide Derived from Bovine αs1-Casein |
| Q37139813 | Enhancing Cancer Immunotherapy by Intracellular Delivery of Cell-Penetrating Peptides and Stimulation of Pattern-Recognition Receptor Signaling |
| Q74301350 | Eradication of established tumors by CD8+ T cell adoptive immunotherapy |
| Q59652622 | Establishment of tissue-specific tolerance is driven by regulatory T cells selected by thymic epithelium |
| Q48731631 | Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette‐Guérin treatment |
| Q36399108 | Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells |
| Q39710346 | Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours |
| Q40320998 | Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism |
| Q42815596 | Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease |
| Q82538989 | Expression of cancer testis antigens in head and neck squamous cell carcinomas |
| Q31036179 | Expression of cancer/testis antigens in cutaneous T cell lymphomas |
| Q50849682 | Expression of fusion IL2-B7.1(IgV+C) and effects on T lymphocytes |
| Q57221651 | Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies |
| Q24615166 | Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma |
| Q33956237 | Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity |
| Q36232655 | Function of tumor necrosis factor receptor family members on regulatory T-cells |
| Q24673923 | G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis |
| Q35146599 | GM-CSF-secreting melanoma vaccines |
| Q24792808 | Gene Therapy Applications to Cancer Treatment |
| Q42969880 | Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells |
| Q71011963 | Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients |
| Q41062769 | Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules |
| Q40259357 | Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma. |
| Q41625946 | Genes coding for melanoma antigens recognised by cytolytic T lymphocytes |
| Q34983184 | Genetic changes occurring in established tumors rapidly stimulate new antibody responses |
| Q35298122 | Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles |
| Q40855690 | Genetically Modified Tumor Cell Vaccines |
| Q38945576 | Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies |
| Q33706382 | Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. |
| Q37823518 | Guiding the “misguided” – functional conditioning of dendritic cells for the DC‐based immunotherapy against tumours |
| Q77723664 | HLA and cancer: from research to clinical impact |
| Q39590200 | HLA antigen expression in enteropathy associated T cell lymphoma |
| Q38839148 | HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy |
| Q34382215 | HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. |
| Q33406039 | High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study. |
| Q35946213 | Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model |
| Q47816653 | Human cortactin as putative cancer antigen |
| Q54427491 | Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire |
| Q41521980 | Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? |
| Q74071787 | IFNgamma secretion following stimulation with total tumor peptides from autologous human tumors |
| Q35950374 | IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. |
| Q40947449 | IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells |
| Q55300547 | IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. |
| Q61623395 | IL-6-Encoding Tumor Antigen Generates Potent Cancer Immunotherapy Through Antigen Processing and Anti-apoptotic Pathways |
| Q30790800 | Identification and characterization of 9D7, a novel human protein overexpressed in renal cell carcinoma |
| Q46430404 | Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. |
| Q34429991 | Identification of Prostate-Specific G-Protein Coupled Receptor as a Tumor Antigen Recognized by CD8+ T Cells for Cancer Immunotherapy |
| Q24647904 | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
| Q30436422 | Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide |
| Q24569553 | Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens |
| Q36369709 | Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis |
| Q36369960 | Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells |
| Q41122596 | Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). |
| Q34190494 | Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA‐A26‐restricted CTL |
| Q34335039 | Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure |
| Q34341797 | Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37. |
| Q35433402 | Image analyzer-based assessment of tumor-infiltrating T cell subsets and their prognostic values in colorectal carcinomas |
| Q42534814 | Immune Mechanisms Are Major Players in Cancer |
| Q58700648 | Immune and genomic signatures in oral (head and neck) cancer |
| Q48395553 | Immune cell infiltrates in atypical teratoid/rhabdoid tumors |
| Q81308391 | Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes |
| Q89556686 | Immune crosstalk in cancer progression and metastatic spread: a complex conversation |
| Q57791068 | Immune regulation of metastasis: mechanistic insights and therapeutic opportunities |
| Q47386754 | Immune response modulatory effect of Emilia sonchifolia (L.) DC: an in vivo experimental study |
| Q37178041 | Immune surveillance against a solid tumor fails because of immunological ignorance |
| Q39057617 | Immune targets and neoantigens for cancer immunotherapy and precision medicine |
| Q34273146 | Immunity against solid tumors? |
| Q33215427 | Immunity to breast cancer in mice immunized with fibroblasts transfected with a cDNA expression library derived from small numbers of breast cancer cells |
| Q41455932 | Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy |
| Q35177548 | Immunodeficiency and cancer: prospects for correction |
| Q38013715 | Immunogene Therapy |
| Q39739073 | Immunoglobulin G from breast cancer patients in stage I stimulates muscarinic acetylcholine receptors in MCF7 cells and induces proliferation. Participation of nitric oxide synthase-derived nitric oxide. |
| Q34074742 | Immunologic approaches to antigen discovery for cancer vaccines |
| Q49328057 | Immunologic approaches to the treatment of cancer |
| Q33606137 | Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma |
| Q34374572 | Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity |
| Q41701856 | Immunological ignorance of silent antigens as an explanation of tumor evasion |
| Q33393451 | Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice - lessons for tumor immunity |
| Q87000284 | Immunomodulatory activity of macromolecular polysaccharide isolated from Grifola frondosa |
| Q40309584 | Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells |
| Q41349062 | Immunotherapy I: Cyclosine gene transfer strategies |
| Q41349071 | Immunotherapy II: Antigens, receptors and costimulation |
| Q56898563 | Immunotherapy for Advanced Melanoma |
| Q39308337 | Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options |
| Q100425508 | Immunotherapy for Localized Prostate Cancer: The Next Frontier? |
| Q36133140 | Immunotherapy for pancreatic cancer - science driving clinical progress |
| Q73051174 | Immunotherapy in hepatocellular carcinoma |
| Q41646149 | Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity |
| Q36243536 | Immunotherapy of cancer in 2012 |
| Q40741662 | Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. |
| Q41694485 | Immunotherapy, including gene therapy, for metastatic melanoma |
| Q34172095 | Immunotherapy: on the edge between experimental and clinical oncology |
| Q22251059 | Immunotherapy: past, present and future |
| Q42549680 | Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning |
| Q41370602 | Implications for immunosurveillance of altered HLA class I phenotypes in human tumours |
| Q34080911 | Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2. |
| Q39628849 | In vitro selective depletion of CD4(+)CD25(+) regulatory T-cells from PBMC using anti-tac-SAP. |
| Q35996832 | In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites |
| Q40915514 | In vivo acquired mechanisms of tumor cells local defense against the host innate immunity effectors: implication in specific antitumor immunity |
| Q51987584 | In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells |
| Q36959354 | In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. |
| Q33178945 | In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes |
| Q37186903 | In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). |
| Q53437611 | In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells |
| Q36365628 | Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses |
| Q40498268 | Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy. |
| Q40851412 | Increased frequency of antigen-specific CD8(+) cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma |
| Q79268799 | Induction of CD8 T-cell-Ifn-γ response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma |
| Q36438003 | Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. |
| Q37724672 | Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells |
| Q64968662 | Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates. |
| Q34577679 | Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma |
| Q51772560 | Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study |
| Q34182039 | Innovations and strategies for the development of anticancer vaccines |
| Q44945953 | Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. |
| Q36600110 | Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression |
| Q74446001 | Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity |
| Q45878031 | Interleukin-12 gene therapy for hepatocellular carcinoma: a dream come true? |
| Q34785774 | Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy |
| Q34210036 | Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer |
| Q45422890 | Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. |
| Q37229840 | Intravital imaging of CD8+ T cell function in cancer |
| Q95491344 | Introduction |
| Q24535835 | Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade |
| Q37592596 | Involvement of a non-human sialic Acid in human cancer |
| Q40782201 | Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. |
| Q73543870 | Large scale and clinical grade purification of syndecan-1+ malignant plasma cells |
| Q71519622 | Live recombinant Listeria monocytogenes as an immunotherapeutic agent for experimental tumors |
| Q52353493 | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. |
| Q36936462 | Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation |
| Q37520816 | Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy |
| Q36367205 | Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens |
| Q39533432 | MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing |
| Q46899687 | MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor |
| Q34414647 | MHC antigens and tumor escape from immune surveillance |
| Q92364680 | MHC/HLA Class I Loss in Cancer Cells |
| Q36750601 | Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer |
| Q36241838 | Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity |
| Q35138209 | Mapping of NRAGE domains reveals clues to cell viability in BMP signaling |
| Q30305778 | Melanoma Peptide Vaccines |
| Q73293803 | Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1 |
| Q38081911 | Melanoma immunotherapy: historical precedents, recent successes and future prospects. |
| Q91889747 | Melanoma vaccines: clinical status and immune endpoints |
| Q38646096 | Melanoma: Clinical Presentations |
| Q73923165 | Melanomas that develop within the eye inhibit lymphocyte proliferation |
| Q39367096 | Metabolism shapes the tumor microenvironment |
| Q33930139 | Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis |
| Q35214671 | Minor histocompatibility antigens in human stem cell transplantation |
| Q39506976 | Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond |
| Q40966308 | Monomorphic HLA class I-(non-A, non-B) expression on Ewing's tumor cell lines, modulation by TNF-alpha and IFN-gamma. |
| Q36366124 | Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo |
| Q26823251 | Myeloid Suppressor Cells and Immune Modulation in Lung Cancer |
| Q39144502 | Natural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells |
| Q37582007 | Natural killer cell cytotoxicity: how do they pull the trigger? |
| Q29619194 | Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self |
| Q46969749 | Neoantigen prediction and the need for validation |
| Q36963359 | Neoantigen: A Long March toward Cancer Immunotherapy |
| Q40175703 | New strategy for the identification of squamous carcinoma antigens that induce therapeutic immune responses in tumor-bearing mice |
| Q41202952 | New therapeutic approaches based on gene transfer techniques |
| Q73361298 | Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells |
| Q36421272 | Non-classical HLA-G antigen and its role in the cancer progression |
| Q34912810 | Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas |
| Q21560837 | Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth |
| Q47954878 | Novel polysaccharide adjuvant from the roots of Actinidia eriantha with dual Th1 and Th2 potentiating activity |
| Q89583558 | Novel tumour antigens and the development of optimal vaccine design |
| Q40531368 | On course for a cancer vaccine |
| Q34037625 | Oncology Meets Immunology: The Cancer-Immunity Cycle |
| Q40640949 | Ontogeny of Xenopus NK cells in the absence of MHC class I antigens |
| Q51190513 | Optimization of epicutaneous immunization for the induction of CTL. |
| Q39265240 | Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity |
| Q38614781 | Optimizing tumor immune response through combination of radiation and immunotherapy. |
| Q35855054 | Overview of melanoma vaccines and promising approaches |
| Q59799655 | PTEN Hamartoma Tumor Syndrome and Immune Dysregulation |
| Q44426725 | Paradoxical effect of trichloroacetic acid (TCA) on ultraviolet B-induced skin tumor formation. |
| Q40414747 | Peptide binding to MHC class I molecules: implications for antigenic peptide prediction |
| Q71802824 | Peptide vaccination against cancer? |
| Q41747642 | Peptide-Major Histocompatibility Complex Class I Complex: From the Structural and Molecular Basis to Pharmacological Principles and Therapeutic Applications |
| Q71420846 | Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen |
| Q43546523 | Perforin dependence of natural killer cell-mediated tumor control in vivo |
| Q80095168 | Permeability of phospholipid vesicles to the tumor antigen epitope gp100(280-288) |
| Q37540578 | Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. |
| Q45880048 | Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors |
| Q33738279 | Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma |
| Q37384753 | Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity |
| Q42988551 | Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses |
| Q38686046 | Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy |
| Q36580586 | Present and future of lung cancer vaccines |
| Q34003932 | Principles of adoptive T cell cancer therapy |
| Q55204931 | Production of murine leukemia RLmale1 rejection antigen peptide pRL1a by proteolysis of natural precursor pRL1b. |
| Q37322987 | Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer |
| Q50959680 | Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma |
| Q37316723 | Progressive Increase of Regulatory T Cells and Decrease of CD8+ T Cells and CD8+ T Cells/Regulatory T Cells Ratio during Colorectal Cancer Development |
| Q33249959 | Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells |
| Q33588526 | Prospects for the therapeutic use of anticancer vaccines |
| Q42428717 | Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. |
| Q34216825 | Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors |
| Q74233043 | Rational approaches to immune regulation |
| Q47887661 | Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity |
| Q38248440 | Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies |
| Q37867102 | Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems |
| Q24602728 | Recombinant Newcastle disease virus as a vaccine vector for cancer therapy |
| Q36366282 | Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor |
| Q27004674 | Reflections upon human cancer immune responsiveness to T cell-based therapy |
| Q71802858 | Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides |
| Q56907971 | Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition |
| Q40589436 | Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). |
| Q36982171 | Regulatory T cells: potential target in anticancer immunotherapy |
| Q74764579 | Requirement of the CD8+ or CD4+ T lymphocyte subsets for the rejection of lymphoma and fibrosarcoma grafts studied in gene knockout hosts |
| Q53400179 | Resistance to Marek's disease herpesvirus-induced lymphoma is multiphasic and dependent on host genotype |
| Q56545832 | Retracted: Apoptosis of CT26 colorectal cancer cells induced by Clostridium difficile toxin A stimulates potent anti-tumor immunity |
| Q41712931 | Review: Dendritic Cells and Cancer: Progress Toward a New Cellular Therapy |
| Q30769959 | Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity |
| Q59061007 | Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction |
| Q74137961 | Routine Lymph Node Dissection in the Treatment of Early Stage Cancer:Are We Doing the Right Thing? |
| Q36272617 | RumMAGE-D the members: structure and function of a new adaptor family of MAGE-D proteins |
| Q31026971 | SAGE mRNA expression in advanced-stage lung cancers |
| Q51972264 | Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma |
| Q24651238 | Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides |
| Q39609814 | Selective cancer-germline gene expression in pediatric brain tumors |
| Q36375095 | Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells |
| Q36380506 | Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy |
| Q30863574 | Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities |
| Q30969714 | Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen |
| Q37562613 | Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas |
| Q41576069 | Serological analysis of human tumor antigens: molecular definition and implications |
| Q55866684 | Serological detection of cutaneous T-cell lymphoma-associated antigens |
| Q24544114 | Serological detection of cutaneous T-cell lymphoma-associated antigens |
| Q41642426 | Serological identification of human tumor antigens |
| Q34003592 | Shaping the repertoire of tumor-infiltrating effector and regulatory T cells |
| Q41107288 | Signal minus 1: a key factor in immunological tolerance to tissue-specific self antigens? |
| Q39398295 | Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses |
| Q40432719 | Soft tissue sarcoma therapy: prospects for future studies |
| Q87798826 | Spontaneous Regression of Endobronchial Carcinoid Tumor |
| Q37049451 | Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide |
| Q80686784 | Spontaneous regression of cutaneous head and neck melanoma: implications for the immunologic control of neoplasia |
| Q33957705 | Strategies for immunotherapy of cancer |
| Q36376346 | Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide |
| Q77158682 | Structural principles that govern the peptide-binding motifs of class I MHC molecules |
| Q39912679 | Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells |
| Q40813537 | Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein |
| Q33676058 | T cell receptor usage in malignant diseases |
| Q71118203 | T cell tolerance and activation to a transgene-encoded tumor antigen |
| Q36210864 | T cell-mediated immunotherapy of metastases: state of the art in 2005. |
| Q34414412 | T cells take aim at cancer |
| Q35918501 | T-cell epitope peptide vaccines. |
| Q38372371 | TANTIGEN: a comprehensive database of tumor T cell antigens |
| Q37385949 | Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. |
| Q33638172 | Targeting p53 as a general tumor antigen |
| Q45732747 | Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen |
| Q36319582 | Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma |
| Q77198669 | The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production |
| Q33542332 | The Fas counterattack: cancer as a site of immune privilege |
| Q57240725 | The Labyrinthine Ways of Cancer Immunotherapy–T Cell, Tumor Cell Encounter: “How Do I Lose Thee? Let Me Count the Ways” |
| Q45974146 | The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors |
| Q57492021 | The Potential of CAR T Cell Therapy in Pancreatic Cancer |
| Q48121576 | The Quantity of Autocrine IL-2 Governs the Expansion Potential of CD8+ T Cells |
| Q52597551 | The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer |
| Q37491118 | The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. |
| Q35047632 | The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma |
| Q83177178 | The contribution of dendritic cells to immune responses against urological cancers |
| Q36555524 | The determinants of tumour immunogenicity |
| Q73017177 | The effect of butylated hydroxytoluene on selected immune surveillance parameters in rats bearing enzyme-altered hepatic preneoplastic lesions |
| Q57959584 | The functional half-life of H-2Kd-restricted T cell epitopes on living cells |
| Q35136610 | The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma |
| Q36586011 | The identification of CD4 + T cell epitopes with dedicated synthetic peptide libraries |
| Q41621164 | The immune response in halo nevi |
| Q30882731 | The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan |
| Q33836317 | The immunomodulatory role of CD4-positive cytotoxic T-lymphocytes in health and disease |
| Q74787680 | The immunopharmacology of head and neck cancer: an UPDATE |
| Q34447434 | The impact of immune responses on lung cancer and the development of new treatment modalities. |
| Q53620667 | The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma |
| Q35940447 | The mouse mammary tumor virus env gene is the source of a CD8+ T-cell-stimulating peptide presented by a major histocompatibility complex class I molecule in a murine thymoma. |
| Q41202720 | The nature of the antigen. |
| Q52047223 | The opposite effect of tumor-infiltrating natural killer cells on in vivo priming of tumor-specific CD8+ T cells and CD4+ T cells |
| Q26799896 | The past, present and future of immunotherapy against tumor |
| Q33620367 | The prevalence and expression pattern of melanoma-associated antigen 1 in esophageal squamous cell carcinoma: a historical cohort study |
| Q38101803 | The repertoire of human tumor-associated epitopes — identification and selection of antigens and their application in clinical trials |
| Q34232543 | The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity |
| Q46816755 | The role of TGF-beta-1 protein and TGF-beta-R-1 receptor in immune escape mechanism in bladder cancer |
| Q33807772 | The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice |
| Q35107549 | The role of regulatory T cells in controlling immunologic self-tolerance |
| Q41647843 | The role of the bystander effect in suicide gene therapy |
| Q36368460 | The use of mass spectrometry to identify antigens from proteasome processing |
| Q35945206 | Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen |
| Q35071688 | Therapeutic vaccination with tumor cells that engage CD137. |
| Q64381308 | Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells |
| Q36366108 | Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines |
| Q80625739 | Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do |
| Q90265999 | Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology |
| Q47193763 | Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. |
| Q41088136 | Transient Expression of SV 40 Large T Antigen by Cre/LoxP-Mediated Site-Specific Deletion in Primary Human Tumor Cells |
| Q57221250 | Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma |
| Q36084026 | Transloading of tumor antigen-derived peptides into antigen-presenting cells |
| Q54200911 | Trap1a is an X-linked and cell-intrinsic regulator of thymocyte development. |
| Q51799863 | Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. |
| Q34483345 | Trial Watch: Peptide-based anticancer vaccines |
| Q36476100 | Trial watch: Peptide vaccines in cancer therapy |
| Q57082680 | Trial watch: peptide-based vaccines in anticancer therapy |
| Q40433328 | Tumor Heterogeneity and Immunotherapy of Cancer |
| Q45861119 | Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor |
| Q40932118 | Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? |
| Q36380515 | Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. |
| Q77442035 | Tumor immunity in mice immunized with fibroblasts transfected with tumor DNA |
| Q41455939 | Tumor immunotherapy by vaccination with cytokine gene transfected cells. |
| Q35671699 | Tumor vaccines. |
| Q46610438 | Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention |
| Q41044428 | Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma |
| Q73592153 | Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats |
| Q36167792 | Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen |
| Q48353734 | Tumor-specific killer cells in paraneoplastic cerebellar degeneration |
| Q34265381 | Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens |
| Q41292381 | Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck |
| Q47901582 | Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-γ) and IL-12 and fluctuations in association with disease activity |
| Q43196387 | Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells |
| Q40465714 | T‐Cell Receptor Usage of Major Histocompatibility Complex Class I Restricted Peptide‐Specific T‐Lymphocytes |
| Q92541449 | Understanding heterogeneous tumor microenvironment in metastatic melanoma |
| Q36017877 | Understanding the response to immunotherapy in humans |
| Q38551549 | Use of cellular and cytokine adjuvants in the immunotherapy of cancer |
| Q36367022 | Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes |
| Q34395494 | Utility of Clostridium difficile toxin B for inducing anti-tumor immunity. |
| Q36365832 | Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen |
| Q34303192 | VEGF as a mediator of tumor-associated immunodeficiency |
| Q38991394 | VSIG4 expression on macrophages facilitates lung cancer development. |
| Q74686412 | Vaccination with Dendritic Cells Inhibits the Growth of Hepatic Metastases in B6 Mice |
| Q35779384 | Vaccination with T cell-defined antigens |
| Q34439914 | Vaccines in oncology: background and clinical potential |
| Q73599532 | [Contribution to the detection of Melan-A/Mart-1 specific CD8+ T cells in surgery of melanoma. Preliminary study] |
| Q37383437 | beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. |
| Q39013357 | mRNA Cancer Vaccines |
| Q36521595 | pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens |